Ablynx annouces a novel preclinical development candidate targeting IL6R
30-Jun-2009 -
Ablynx announced that it has advanced ALX-0061, a new Nanobody®-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases.
ALX-0061 is a selective, low molecular weight biologic, binding to the IL6 receptor (IL6R). It has a very high ...
inflammation
inflammatory diseases
molecular weight